Non-carbapenem Drugs for Patients with Bacteremia caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Piperacillin-Tazobactam
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Carbapenems are recommended for treating bacteremia caused by extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae (ESBL-E). However, this has resulted in a significant rise in the utilization of carbapenems in cases of ESBL-E infection. We evaluated the clinical outcomes of patients with ESBL-E bacteremia treated with non-carbapenem antimicrobials. Methods: We conducted a retrospective case-control study of a cohort of patients with documented ESBL-E bacteremia from January 2021 to December 2021. The patients were divided into two groups according to whether they received non-carbapenem or carbapenem therapy. The rates of treatment failure, 30-day mortality and microbiologic failure, and the durations of hospitalization and of antimicrobial therapy were compared between the two groups. Antimicrobial susceptibility testing and phenotypic identification of ESBL-E were performed using the Vitek 2 system. Results: Of 118 patients with ESBL-E bacteremia, 54 received non-carbapenem drugs (non-carbapenem group [NCG]) and 64 received carbapenems (carbapenem group [CG]). Treatment failure at 30 days occurred in 16.7% of the patients in the NCG and in 18.8% in the CG (p = 0.65). The 30-day mortality rate was 14.8% in the NCG and 17.2% in the CG (p = 0.63). Extra-urinary tract infection and prior antimicrobial therapy within 30 days were risk factors for treatment failure in patients with ESBL-E bacteremia. The clinical outcomes did not differ significantly between the two groups, challenging the prevailing preference for carbapenems in the treatment of ESBL-E bacteremia. Conclusions: Non-carbapenem antimicrobials such as piperacillin/tazobactam are recommended for patients with mild ESBL-E bacteremia in South Korea.
Abstract
Background/Aims: Carbapenems are recommended for treating bacteremia caused by extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae (ESBL-E). However, this has resulted in a significant rise in the utilization of carbapenems in cases of ESBL-E infection. We evaluated the clinical outcomes of patients with ESBL-E bacteremia treated with non-carbapenem antimicrobials. Methods: We conducted a retrospective case-control study of a cohort of patients with documented ESBL-E bacteremia from January 2021 to December 2021. The patients were divided into two groups according to whether they received non-carbapenem or carbapenem therapy. The rates of treatment failure, 30-day mortality and microbiologic failure, and the durations of hospitalization and of antimicrobial therapy were compared between the two groups. Antimicrobial susceptibility testing and phenotypic identification of ESBL-E were performed using the Vitek 2 system. Results: Of 118 patients with ESBL-E bacteremia, 54 received non-carbapenem drugs (non-carbapenem group [NCG]) and 64 received carbapenems (carbapenem group [CG]). Treatment failure at 30 days occurred in 16.7% of the patients in the NCG and in 18.8% in the CG (p = 0.65). The 30-day mortality rate was 14.8% in the NCG and 17.2% in the CG (p = 0.63). Extra-urinary tract infection and prior antimicrobial therapy within 30 days were risk factors for treatment failure in patients with ESBL-E bacteremia. The clinical outcomes did not differ significantly between the two groups, challenging the prevailing preference for carbapenems in the treatment of ESBL-E bacteremia. Conclusions: Non-carbapenem antimicrobials such as piperacillin/tazobactam are recommended for patients with mild ESBL-E bacteremia in South Korea.
참고문헌 (18)
- Castanheira M, "Extended-spectrum β-lactamases : an update on their characteristics, epidemiology and detection", JAC Antimicrob Resist, 3, pp.dlab092~ (2021)
- Jernigan JA, "Multidrug-resistant bacterial infections in U. S. hospitalized patients, 2012-2017", N Engl J Med, 382, pp.1309~1319 (2020)
- Karlowsky JA, "Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019", Int J Antimicrob Agents, 59, pp.106535~ (2022)
- Baek YJ, "Risk factors for extended-spectrum-β-lactamase-producing Escherichia coli in community-onset bloodstream infection : impact on long-term care hospitals in Korea", Ann Lab Med, 41, pp.455~462 (2021)
- Johnson JR, "Molecular epidemiological analysis of Escherichia coli sequence type ST131(O25 : H4)and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009", Antimicrob Agents Chemother, 56, pp.2364~2370 (2012)
- Lee CM, "Disease burden of bacteraemia with extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales in Korea", J Hosp Infect, 144, pp.85~93 (2024)
- Tamma PD, "Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales(ESBL-E), carbapenem-resistant Enterobacterales(CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance(DTR-P. aeruginosa)", Clin Infect Dis, 72, pp.e169~e183 (2021)
- Seo YB, "Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli", BMC Infect Dis, 17, pp.404~ (2017)
- Kim YJ, "Change in the annual antibiotic susceptibility of Escherichia coli in community-onset urinary tract infection between 2008 and 2017 in a tertiary care hospital in Korea", J Korean Med Sci, 34, pp.e228~ (2019)
- Ma J, "Global spread of carbapenem-resistant Enterobacteriaceae : epidemiological features, resistance mechanisms, detection and therapy", Microbiol Res, 266, pp.127249~ (2023)
- Paterson DL, "International prospective study of Klebsiella pneumoniae bacteremia : implications of extended-spectrum beta-lactamase production in nosocomial Infections", Ann Intern Med, 140, pp.26~32 (2004)
- Harris PNA, "Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance : a randomized clinical trial", JAMA, 320, pp.984~994 (2018)
- Henderson A, "Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin", tazobactam or meropenem from the MERINO study, 2021, pp.73, e3842~e3850
- Kang CI, "Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli over a 6-year period", J Korean Med Sci, 28, pp.998~1004 (2013)
- Kim YC, "Risk factors and microbiological features of recurrent Escherichia coli bloodstream infections", PLoS One, 18, pp.e0280196~ (2023)
- Choi HJ, "Characteristics of Escherichia coli urine isolates and risk factors for secondary bloodstream infections in patients with urinary tract infections", Microbiol Spectr, 10, pp.e0166022~ (2022)
- Sharara SL, "Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing organisms?", Clin Infect Dis, 71, pp.e331~e337 (2020)
- Chow JW, "Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia : a commentary", Int J Antimicrob Agents, 11, pp.7~12 (1999)